Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value.
The Byk LIA-mat CA125 II assay was compared with the Centocor IRMA CA125 II. Serum samples studied (n = 1012) were obtained from 652 apparently healthy females, 61 pregnant women, and 299 patients with benign and malignant gynecological tumors. The CA125 II assay value at the 95th percentile of the total healthy group was 29 kU/L for the LIA-mat and 32 kU/L for the Centocor assay. For the LIA-mat assay the 95th percentile was 31 kU/L (Centocor 36 kU/L) for the group < 45 years and 21 kU/L (Centocor 25 kU/L) for women > 55 years of age. By using ROC curves we found the optimal pretreatment Byk LIA-mat CA125 II value differentiating between benign and malignant ovarian tumors to be 95 kU/L. Pretreatment CA125 values > 1000 kU/L were detected in serum samples of patients with advanced epithelial ovarian cancer.
Bonfrer
J M
JM
Department of Clinical Chemistry, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Amsterdam, The Netherlands.
Korse
C M
CM
Verstraeten
R A
RA
van Kamp
G J
GJ
Hart
G A
GA
Kenemans
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000097:blood*; D005189:False Positive Reactions; D005260:Female; D005831:Genital Diseases, Female / Q000097:blood* / Q000175:diagnosis; D005833:Genital Neoplasms, Female / Q000097:blood* / Q000175:diagnosis; D006801:Humans; D007118:Immunoassay / Q000379:methods; D008875:Middle Aged; D011247:Pregnancy; D012372:ROC Curve; D012016:Reference Values; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D018394:CA-125 Antigen